$1.07 Trillion is the total value of Casdin Capital, LLC's 31 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 27.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ONCE | Sell | SPARK THERAPEUTICS INC | $90,585,824,000 | +84522.5% | 884,800 | -5.9% | 8.48% | -27.9% |
| NVTA | Buy | INVITAE CORP | $90,202,118,000 | +174968.2% | 3,838,388 | +74.5% | 8.44% | +49.2% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $88,670,200,000 | +130424.0% | 940,000 | +10.8% | 8.30% | +11.2% |
| CDXS | Buy | CODEXIS INC | $86,519,885,000 | +208015.6% | 5,073,780 | +150.6% | 8.10% | +77.3% |
| SAGE | SAGE THERAPEUTICS INC | $73,236,000,000 | +115014.7% | 400,000 | 0.0% | 6.86% | -1.9% | |
| MYOK | MYOKARDIA INC | $64,429,900,000 | +96341.8% | 1,285,000 | 0.0% | 6.03% | -17.8% | |
| FATE | FATE THERAPEUTICS INC | $51,765,000,000 | +115436.6% | 2,550,000 | 0.0% | 4.84% | -1.5% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $50,903,250,000 | +139924.9% | 335,000 | +9.8% | 4.76% | +19.3% |
| BLUE | Buy | BLUEBIRD BIO INC | $47,382,000,000 | +84142.2% | 372,500 | +4.2% | 4.44% | -28.2% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $47,164,000,000 | +113315.9% | 650,000 | +46.1% | 4.42% | -3.3% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $44,296,035,000 | +101648.1% | 3,003,121 | +13.6% | 4.15% | -13.3% |
| BLFS | BIOLIFE SOLUTIONS INC | $39,408,375,000 | +90604.5% | 2,428,571 | 0.0% | 3.69% | -22.7% | |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $36,534,900,000 | +92604.6% | 965,000 | -4.5% | 3.42% | -21.0% |
| VYGR | VOYAGER THERAPEUTICS INC | $30,706,202,000 | +142117.6% | 1,128,075 | 0.0% | 2.87% | +21.2% | |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $24,690,600,000 | +109189.1% | 495,000 | +47.8% | 2.31% | -6.9% |
| ILMN | ILLUMINA INC | $22,089,000,000 | +118396.9% | 60,000 | 0.0% | 2.07% | +1.0% | |
| GNMK | GENMARK DIAGNOSTICS INC | $21,838,850,000 | +91436.8% | 3,365,000 | 0.0% | 2.04% | -22.0% | |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $20,100,347,000 | – | 463,125 | +100.0% | 1.88% | – |
| GRTS | Buy | GRITSTONE ONCOLOGY INC | $19,717,800,000 | +132198.7% | 1,770,000 | +58.0% | 1.85% | +12.8% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $18,714,229,000 | +88605.6% | 1,523,960 | -2.1% | 1.75% | -24.4% |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $16,478,100,000 | +159835.0% | 1,530,000 | +41.7% | 1.54% | +36.2% |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $15,780,000,000 | +99276.5% | 300,000 | 0.0% | 1.48% | -15.3% | |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $14,579,650,000 | +150112.8% | 745,000 | +112.9% | 1.36% | +28.0% |
| EDIT | EDITAS MEDICINE INC | $11,875,200,000 | +101086.1% | 480,000 | 0.0% | 1.11% | -13.7% | |
| ALEC | Buy | ALECTOR INC | $10,189,059,000 | +164319.2% | 551,039 | +66.5% | 0.95% | +40.1% |
| TWST | New | TWIST BIOSCIENCE CORP | $8,703,000,000 | – | 300,000 | +100.0% | 0.82% | – |
| DNLI | Buy | DENALI THERAPEUTICS INC | $8,304,000,000 | +357522.7% | 400,000 | +300.0% | 0.78% | +204.7% |
| CDNA | CAREDX INC | $7,198,000,000 | +114081.5% | 200,000 | 0.0% | 0.67% | -2.6% | |
| STOK | New | STOKE THERAPEUTICS INC | $2,479,450,000 | – | 85,000 | +100.0% | 0.23% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $2,442,000,000 | – | 60,000 | +100.0% | 0.23% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCadr | $1,399,000,000 | – | 100,000 | +100.0% | 0.13% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -80,000 | -100.0% | -0.57% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -550,000 | -100.0% | -0.76% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -70,000 | -100.0% | -1.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.